These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 6324566)

  • 1. [Calcium-phosphorus changes in chronic anticonvulsant therapy: effects of the administration of 25-hydroxyvitamin D3 on secondary hyperparathyroidism].
    Bianchini G; Mazzaferro S; Mancini U; Bianchi AR; Donato G; Massimetti C; Faedda MR; Sideri G; Coen G
    Acta Vitaminol Enzymol; 1983; 5(4):229-34. PubMed ID: 6324566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium and phosphorus homeostasis in man. Effect of corticosteroids.
    Lukert BP; Adams JS
    Arch Intern Med; 1976 Nov; 136(11):1249-53. PubMed ID: 185973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison.
    Maung HM; Elangovan L; Frazão JM; Bower JD; Kelley BJ; Acchiardo SR; Rodriguez HJ; Norris KC; Sigala JF; Rutkowski M; Robertson JA; Goodman WG; Levine BS; Chesney RW; Mazess RB; Kyllo DM; Douglass LL; Bishop CW; Coburn JW
    Am J Kidney Dis; 2001 Mar; 37(3):532-43. PubMed ID: 11228177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Long-term anticonvulsant therapy and calcium and phosphorus metabolism].
    Bergonzi P; De Rosa G; Mazza S; Mennuni G; Zuppi PL
    Riv Neurol; 1979; 49(1):72-81. PubMed ID: 451400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent recurrence of secondary hyperparathyroidism after pulse oral calcitriol withdrawal in PD patients.
    Bajo MA; Selgas R; Possante C; Aguilera A; Sánchez C; Diaz C; de Alvaro F; Martinez ME
    Adv Perit Dial; 1997; 13():239-43. PubMed ID: 9360690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RenaGel efficacy in severe secondary hyperparathyroidism.
    Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
    Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Early treatment of secondary hyperparathyroidism in moderate renal insufficiency: low-phosphorus diet versus calcium carbonate].
    Aresté N; Amor J; Cambil T; Salgueira M; Sánchez-Palencia R; Páez C; Gómez O; Palma A
    Nefrologia; 2003; 23 Suppl 2():64-8. PubMed ID: 12778857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
    Lindberg J; Martin KJ; González EA; Acchiardo SR; Valdin JR; Soltanek C
    Clin Nephrol; 2001 Oct; 56(4):315-23. PubMed ID: 11680662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of bariatric surgery on vitamin D status and secondary hyperparathyroidism: a prospective study.
    Sánchez-Hernández J; Ybarra J; Gich I; De Leiva A; Rius X; Rodríguez-Espinosa J; Pérez A
    Obes Surg; 2005; 15(10):1389-95. PubMed ID: 16354517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of sevelamer on mineral metabolism and hyperparathyroidism in Japanese hemodialysis patients.
    Inoue T; Nagatoya K; Kagitani M; Shibahara N; Ueda H; Katsuoka Y; Ohashi S; Kitagawa Y; Nishimoto K; Yasuda H;
    Ther Apher Dial; 2007 Jun; 11(3):210-4. PubMed ID: 17498003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unchanged hypovitaminosis D and secondary hyperparathyroidism in morbid obesity after bariatric surgery.
    Ybarra J; Sánchez-Hernández J; Gich I; De Leiva A; Rius X; Rodríguez-Espinosa J; Pérez A
    Obes Surg; 2005 Mar; 15(3):330-5. PubMed ID: 15826464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of secondary hyperparathyroidism with vitamin D metabolites].
    Stojimirović B; Pejanović S; Djukanović Lj
    Srp Arh Celok Lek; 1994; 122(7-8):197-9. PubMed ID: 17974384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of long-term therapy with calcitriol in patients with moderate renal failure.
    Healy MD; Malluche HH; Goldstein DA; Singer FR; Massry SG
    Arch Intern Med; 1980 Aug; 140(8):1030-3. PubMed ID: 6893118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased serum 24,25-dihydroxyvitamin D concentration during long-term anticonvulsant therapy in adult epileptics.
    Zerwekh JE; Homan R; Tindall R; Pak CY
    Ann Neurol; 1982 Aug; 12(2):184-6. PubMed ID: 6982022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulse intravenous calcitriol therapy of secondary hyperparathyroidism in peritoneal dialysis patients.
    Wadhwa NK; Suh H; Howell N; Cabralda T; Sokunbi D; Solomon M
    Adv Perit Dial; 1993; 9():260-3. PubMed ID: 8105939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sleep disturbances before and after parathyroidectomy for secondary hyperparathyroidism.
    Chou FF; Lee CH; Chen JB; Huang SC; Lee CT
    Surgery; 2005 Apr; 137(4):426-30. PubMed ID: 15800490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Medical-surgical integrated approach in the treatment of non-paraneoplasic hyperparathyroidism: our experience].
    Pulvirenti D; Aikaterini T; Campagna A; Ignaccolo L; Giustolisi N; Costa E
    Clin Ter; 2008; 159(5):307-10. PubMed ID: 18998031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.
    Coyne D; Acharya M; Qiu P; Abboud H; Batlle D; Rosansky S; Fadem S; Levine B; Williams L; Andress DL; Sprague SM
    Am J Kidney Dis; 2006 Feb; 47(2):263-76. PubMed ID: 16431255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.